EC330, a small-molecule compound, is a potential novel inhibitor of LIF signaling

• 作者: Bindu Santhamma Fangnan Wu Gulzar Ahmed Jianming Wang Kaitlin Kim Kalarickal V.Dileep Kam Y.J.Zhang Klaus Nickisch Ratna K.Vadlamudi Suryavathi Viswanadhapalli Wenwei Hu Xuetian Yue Zhaohui Feng
• 来源期刊: 分子细胞生物学报（英文版）
• 年，卷（期）: 2020,（6）
• 页码范围: 477-480
• 页数: 4页
• 语种: 英文
• DOI: 10.1093/jmcb/mjaa008

摘要

Dear Editor, LIF,a multi-functional cytokine,is frequently overexpressed in many human cancers,including breast,colorectal,and pancreatic cancers (Liu et al.,2013;Li et al.,2014;Yu et al.,2014;Pascual-Garcia et al.,2019;Shiet al.,2019;Wang et al.,2019).LIF overexpression is frequently associated with poor prognosis in human cancers (Liu et al.,2013;Li et al.,2014;Yu et al.,2014).LIF functions through binding to LIF receptor complex composed of LIF receptor (LIF-R) and glycoprotein gp130 (Taga and Kishimoto,1997;Heinrich et al.,2003;Watanabe et al.,2006).